158 related articles for article (PubMed ID: 35635484)
1. Platelet count and plateletcrit: Potential haematological biomarkers for livedoid vasculopathy?
Gao Y; Jin H
Australas J Dermatol; 2022 Aug; 63(3):e200-e205. PubMed ID: 35635484
[TBL] [Abstract][Full Text] [Related]
2. Livedo vasculopathy vs small vessel cutaneous vasculitis: cytokine and platelet P-selectin studies.
Papi M; Didona B; De Pità O; Frezzolini A; Di Giulio S; De Matteis W; Del Principe D; Cavalieri R
Arch Dermatol; 1998 Apr; 134(4):447-52. PubMed ID: 9554296
[TBL] [Abstract][Full Text] [Related]
3. Peripheral neuropathy and livedoid vasculopathy.
Soulages A; Maisonobe T; Auzou P; Petit A; Allenbach Y; Barète S; Skopinski S; Ribeiro E; Jullié ML; Lamant L; Brevet F; Soulages X; Vallat JM; Martin-Négrier ML; Solé G; Duval F; Carla L; Le Masson G; Mathis S
J Neurol; 2022 Jul; 269(7):3779-3788. PubMed ID: 35166926
[TBL] [Abstract][Full Text] [Related]
4. Livedoid vasculopathy and peripheral neuropathy: A retrospective cohort study of 55 Chinese patients and literature review.
Gao Y; Jin H
Int Wound J; 2023 May; 20(5):1498-1505. PubMed ID: 36333819
[TBL] [Abstract][Full Text] [Related]
5. [Vasculitis and vasculopathy].
Marković A
Acta Med Croatica; 2012 Oct; 66 Suppl 1():19-24. PubMed ID: 23193816
[TBL] [Abstract][Full Text] [Related]
6. Baricitinib is potentially effective in the treatment of refractory livedoid vasculopathy.
Han Y; Tu P
Front Immunol; 2022; 13():1008392. PubMed ID: 36389811
[TBL] [Abstract][Full Text] [Related]
7. Histopathological findings in cutaneous small-vessel vasculitis associated with solid-organ malignancy.
Podjasek JO; Wetter DA; Wieland CN; Camilleri MJ; Lohse CM
Br J Dermatol; 2014 Dec; 171(6):1397-401. PubMed ID: 24958433
[TBL] [Abstract][Full Text] [Related]
8. Livedoid vasculopathy in a patient with factor V mutation (Leiden).
Biedermann T; Flaig MJ; Sander CA
J Cutan Pathol; 2000 Sep; 27(8):410-2. PubMed ID: 10955688
[TBL] [Abstract][Full Text] [Related]
9. Analysis of serum levels and cutaneous expression of lipoprotein (a) in 38 patients with livedoid vasculopathy.
Espinel DPGS; Di Giacomo TB; Pincelli TP; Pereira NV; Sotto MN; Kirsner RS; Criado PR
J Cutan Pathol; 2017 Dec; 44(12):1033-1037. PubMed ID: 28901563
[TBL] [Abstract][Full Text] [Related]
10. Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) treated successfully with tissue plasminogen activator.
Deng A; Gocke CD; Hess J; Heyman M; Paltiel M; Gaspari A
Arch Dermatol; 2006 Nov; 142(11):1466-9. PubMed ID: 17116837
[TBL] [Abstract][Full Text] [Related]
11. Associations between coagulation factors and livedoid vasculopathy and the efficacy and safety of rivaroxaban in patients with livedoid vasculopathy: a retrospective study.
Zhao C; Yu M; Cheng X; Li S; Feng S
Clin Exp Dermatol; 2024 Jan; ():. PubMed ID: 38287670
[TBL] [Abstract][Full Text] [Related]
12. Distinct pattern of direct immunofluorescence in livedoid vasculopathy.
Hsiao PF; Wu YH
Am J Dermatopathol; 2010 May; 32(3):240-243. PubMed ID: 20075710
[TBL] [Abstract][Full Text] [Related]
13. Medium-pressure hyperbaric oxygen therapy for livedoid vasculopathy.
Herrera-Sánchez A; Madriagal-Alvarado MJ; Moncayo G; Verdini F
Medicina (B Aires); 2022; 82(4):613-616. PubMed ID: 35904919
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of an anti-TNF-alpha agent in refractory livedoid vasculopathy: a retrospective analysis.
Gao Y; Jin H
J Dermatolog Treat; 2022 Feb; 33(1):178-183. PubMed ID: 32116074
[TBL] [Abstract][Full Text] [Related]
15. Livedoid vasculopathy - a challenging disease.
Vieira R; Bernardes JM; Pinto JA; Costa L
Acta Reumatol Port; 2016; 41(3):273-274. PubMed ID: 27155327
[TBL] [Abstract][Full Text] [Related]
16. Livedoid vasculopathy: long-term follow-up results following hyperbaric oxygen therapy.
Juan WH; Chan YS; Lee JC; Yang LC; Hong HS; Yang CH
Br J Dermatol; 2006 Feb; 154(2):251-5. PubMed ID: 16433793
[TBL] [Abstract][Full Text] [Related]
17. A comprehensive review on pathogenesis, associations, clinical findings, and treatment of livedoid vasculopathy.
Seguí M; Llamas-Velasco M
Front Med (Lausanne); 2022; 9():993515. PubMed ID: 36569162
[TBL] [Abstract][Full Text] [Related]
18. Intravenous Immunoglobulin Therapy in Livedoid Vasculopathy: Retrospective Observation of Clinical Outcome and Patient's Activity Level.
Kofler K; Strölin A; Geiger V; Kofler L
J Cutan Med Surg; 2021 Sep; 25(5):504-510. PubMed ID: 33779349
[TBL] [Abstract][Full Text] [Related]
19. Enhanced functional stability of plasminogen activator inhibitor-1 in patients with livedoid vasculopathy.
Agirbasli M; Eren M; Eren F; Murphy SB; Serdar ZA; Seckin D; Zara T; Cem Mat M; Demirkesen C; Vaughan DE
J Thromb Thrombolysis; 2011 Jul; 32(1):59-63. PubMed ID: 21311952
[TBL] [Abstract][Full Text] [Related]
20. A practical approach to the diagnosis, evaluation, and management of cutaneous small-vessel vasculitis.
Goeser MR; Laniosz V; Wetter DA
Am J Clin Dermatol; 2014 Aug; 15(4):299-306. PubMed ID: 24756249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
